
Merck: FDA has granted MK-2060 Fast Track designation
On August 23, Merck announced that the FDA has granted Fast Track designation to its intravenous anticoagulant drug MK-2060 for reducing the risk of major
On August 23, Merck announced that the FDA has granted Fast Track designation to its intravenous anticoagulant drug MK-2060 for reducing the risk of major